Chronic Diseases Prevention Review (Online ISSN: 2158-0820)

by Zhuo Chen

Chronic Diseases Prevention Review 2023 7(26) 1-15; published online  23 December 2023

Abstract: To analyze the mechanism of Jinhuang Gao in treating eczema by pharmacology. We screened active components and targets of Jinhuang Gao by TCMSP database (Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform), and disease targets through GeneCards database. “Pathway-Component-Target” network was assembled via Cytoscape 3.9.1 software, and PPI network was formulated utilizing STRING database. GO function and KEGG pathway enrichment were analyzed to predict its mechanism. Additionally, SYBYL-X 2.1.1 and PyMOL software were used for molecular docking. 232 components, 122 therapeutic targets, 5835 GO items and 250 pathways were found. Among them, five key components (beta-sitosterol, quercetin, Licochalcone-A, naringenin, and formononetin) and five core targets (EGF, NFKBIA, IL4, MAPK14, and RELA) in the treatment of eczema were found. There are 20 key pathways, including PI3K-Akt signaling pathway, Pathways of neurodegeneration multiple diseases, Relaxin signaling pathway, Calcium signaling pathway, JAK-STAT signaling pathway, etc. Drug components were found to bind better to target proteins. This study preliminarily revealed active components, targets and pathways of Jinhuang Gao in treating eczema.